DAFTAR PUSTAKA

1. Urbonas G, Valius L, Šakalytė G, Petniūnas K, Petniūnienė I. The quality of anticoagulation therapy among warfarin-treated patients with atrial fibrillation in a primary health care setting. Medicina (Lithuania). 21 Januari 2019;55(1).
2. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, dkk. Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2 Januari 2024;149(1).
3. Hartono B, Hanafy DA, Yugo D, Maharani E, Swi Antara IMP, Raharjo SB. Pedoman Tata Laksana Fibrilasi Atrium Non-Valvular. 2 ed. Manuwar M, Yuniadi Y, editor. Jakarta: PT. Trans Medical International; 2019.
4. Sagris M, Vardas EP, Theofilis P, Antonopoulos AS, Oikonomou E, Tousoulis D. Atrial fibrillation: Pathogenesis, predisposing factors, and genetics. Vol. 23, International Journal of Molecular Sciences. MDPI; 2022.
5. Husniyah B, Herwanto B, Handajani NI. Characteristics of Atrial Fibrillation Based On Age, Sex, and Etiology. JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga. 31 Agustus 2020;11(2):86.
6. Munira SL, Puspasari D. Survei Kesehatan Indonesia (SKI) Dalam Angka [Internet]. Bekasi; 2023 Mar [dikutip 3 Mei 2024]. Tersedia pada: https://www.badankebijakan.kemkes.go.id/ski-2023-dalam-angka/
7. Cunha PS, Laranjo S, Heijman J, Oliveira MM. The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates. Vol. 9, Frontiers in Cardiovascular Medicine. Frontiers Media S.A.; 2022.
8. Abdul-Aziz AA, Altawil M, Lyon A, MacEachern M, Richardson CR, Rubenfire M, dkk. Lifestyle Therapy for the Management of Atrial Fibrillation. Vol. 121, American Journal of Cardiology. Elsevier Inc.; 2018. hlm. 1112–7.
9. Menteri Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Tentang Daftar Obat Esensial Nasional (No HK.01.07/Menkes/6477/2021). 13 Oktober 2021 [dikutip 17 Februari 2025];1:1–36. Tersedia pada: https://e-fornas.kemkes.go.id/files/pdf/DOEN%202021.pdf
10. Hindricks G, Potpara T, Kirchhof P, Kühne M, Ahlsson A, Balsam P, dkk. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Vol. 42, European Heart Journal. Oxford University Press; 2021. hlm. 373–498.
11. Fovel LM, Miller CD, Seabury RW, Probst LA, Horvath L. Evaluation of Warfarin Patients with Low Time in Therapeutic Range (TTR) for Transition

to Non-Vitamin-K Oral Anticoagulant (NOAC) Therapy. P T. September 2019;44(9):534.
12. Shikdar S, Vashisht R, T. Bhattacharya P. International Normalized Ratio (INR) [Internet]. StatPearls Publishing. Pennsylvania: StatPearls; 2023 [dikutip 13 Juni 2024]. Tersedia pada: https://www.ncbi.nlm.nih.gov/books/NBK507707/
13. Liang HF, Du X, Zhou YC, Yang XY, Xia SJ, Dong JZ, dkk. Control of anticoagulation therapy in patients with atrial fibrillation treated with warfarin: A study from the Chinese atrial fibrillation registry. Medical Science Monitor. 2019;25:4691–8.
14. Tadesse TA, Tegegne GT, Yadeta D, Chelkaba L, Fenta TG. Anticoagulation control, outcomes, and associated factors in long-term-care patients receiving warfarin in Africa: a systematic review. Vol. 20, Thrombosis Journal. BioMed Central Ltd; 2022.
15. Lilly LS. Pathophysiology of Heart Disease: An Introduction to Cardiovascular Medicine [Internet]. 7th ed. Lilly LS, editor. Philadelphia: WoltersKluwer; 2020 [dikutip 18 Februari 2025]. 296–297 hlm. Tersedia pada: https://www.amazon.com/Pathophysiology-Heart-Disease-Introduction-Cardiovascular/dp/1975120590
16. Choi SE, Sagris D, Hill A, Lip GYH, Abdul-Rahim AH. Atrial fibrillation and stroke. Expert Rev Cardiovasc Ther [Internet]. 8 Januari 2023 [dikutip 18 Juli 2024];21(1):35–56. Tersedia pada: https://www.tandfonline.com/doi/full/10.1080/14779072.2023.2160319#d1e2584
17. Melgaard L, Jensen M, Overvad TF, Larsen TB, Lip GYH, Nielsen PB. Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: A descriptive nationwide cohort study. Int J Clin Pract. 1 Oktober 2020;74(10).
18. Fauchier L, Philippart R, Clementy N, Bourguignon T, Angoulvant D, Ivanes F, dkk. How to define valvular atrial fibrillation? Vol. 108, Archives of Cardiovascular Diseases. Elsevier Masson SAS; 2015. hlm. 530–9.
19. Lip GYH, Jensen M, Melgaard L, Skjøth F, Nielsen PB, Larsen TB. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: Evaluating “valvular heart disease” in a nationwide cohort study. Europace. 1 Januari 2019;21(1):33–40.
20. Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, dkk. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology. 1 Desember 2020;36(12):1847–948.
21. Dorgalaleh A, Favaloro EJ, Bahraini M, Rad F. Standardization of Prothrombin Time/International Normalized Ratio (PT/INR). Vol. 43, International Journal of Laboratory Hematology. Blackwell Publishing Ltd; 2021. hlm. 21–8.
22. Octasari PM, Silvianingsih N. Kesesuaian Nilai INR (International Normalized Ratio) Pasien Kardiovaskuler dengan Terapi Warfarin di Poli

Spesialis Jantung RS Roemani Muhammadiyah Semarang. Cendekia Journal of Pharmacy. 1 Mei 2022;6(1).
23. Katzung BG. Katzung's Basic & Clinical Pharmacology [Internet]. 14th ed. Katzung BG, editor. Vol. 1. San Fransisco: McGraw-Hill Education; 2018 [dikutip 18 Juni 2024]. 614–616 hlm. Tersedia pada: https://accesspharmacy.mhmedical.com/book.aspx?bookID=3382
24. Björck F, Kadhim H, Själander A. Predictors for INR-control in a well-managed warfarin treatment setting. J Thromb Thrombolysis. 15 Februari 2019;47(2):227–32.
25. Luengsupabul S, Methavigul K, Methavigul R. Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin. J Arrhythm. 1 Juni 2020;36(3):425–9.
26. Depkes RI. Kategori umur menurut Depkes RI. Departemen Kesehatan RI [Internet]. 3 Juli 2009 [dikutip 18 Juni 2024];(1):1. Tersedia pada: https://www.scribd.com/doc/151484440/Kategori-Umur-Menurut-Depkes-RI
27. Short SE, Yang YC, Jenkins TM. Sex, Gender, Genetics, and Health. Am J Public Health [Internet]. 10 September 2013 [dikutip 18 Juni 2024];103(Supplement 1):93–100. Tersedia pada: https://ajph.aphapublications.org/doi/10.2105/AJPH.2013.301229?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
28. Sharma P, Dunham A. Pharmacy Calculations. StatPearls [Internet]. 20 Juni 2023 [dikutip 4 Mei 2024];1(1):1. Tersedia pada: https://www.ncbi.nlm.nih.gov/books/NBK560924/
29. Harrison C, Fortin M, van den Akker M, Mair F, Calderon-Larranaga A, Boland F, dkk. Comorbidity versus multimorbidity: Why it matters. Journal of Multimorbidity and Comorbidity. 1 Januari 2021;11:263355652199399.
30. Titi L. Kajian Etik Penelitian Dalam Bidang Kesehatan dengan Melibatkan Manusia Sebagai Subyek. Fakultas Ilmu Kesehatan Universitas Muhammadiyah Jember. 1 Juni 2018;10(1):2087–5053.
31. Siddiqi HK, Vinayagamoorthy M, Gencer B, Ng C, Pester J, Cook NR, dkk. Sex Differences in Atrial Fibrillation Risk: The VITAL Rhythm Study. JAMA Cardiol. 1 Oktober 2022;7(10):1027–35.
32. Volgman AS, Benjamin EJ, Curtis AB, Fang MC, Lindley KJ, Naccarelli G V., dkk. Women and atrial fibrillation. Vol. 32, Journal of Cardiovascular Electrophysiology. John Wiley and Sons Inc; 2021. hlm. 2793–807.
33. Odening KE, Deiß S, Dilling-Boer D, Didenko M, Eriksson U, Nedios S, dkk. Mechanisms of sex differences in atrial fibrillation: Role of hormones and differences in electrophysiology, structure, function, and remodelling. Vol. 21, Europace. Oxford University Press; 2019. hlm. 366–76.
34. Roberts JD, Vittinghoff E, Lu AT, Alonso A, Wang B, Sitlani CM, dkk. Epigenetic Age and the Risk of Incident Atrial Fibrillation. Circulation. 14 Desember 2021;144(24):1899–911.

35. Zathar Z, Karunatilleke A, Fawzy AM, Lip GYH. Atrial Fibrillation in Older People: Concepts and Controversies. Vol. 6, Frontiers in Medicine. Frontiers Media S.A.; 2019.
36. Suryoputri MW, Endriastuti NE, Ilma DL, Azzahra A. Correlation Between Warfarin Levels in the Blood and the Value of Normal INR in Fibrillation Atrium Inpatients. JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice). 30 Mei 2024;14(2):111.
37. Kjerpeseth LJ, Igland J, Selmer R, Ellekjær H, Tveit A, Berge T, dkk. Prevalence and incidence rates of atrial fibrillation in Norway 2004-2014. Heart. 1 Februari 2021;107(3):201–7.
38. Santema BT, Arita VA, Sama IE, Kloosterman M, Van Den Berg MP, Nienhuis HLA, dkk. Pathophysiological pathways in patients with heart failure and atrial fibrillation. Cardiovasc Res. 1 Juli 2022;118(11):2478–87.
39. Frederiksen TC, Dahm CC, Preis SR, Lin H, Trinquart L, Benjamin EJ, dkk. The bidirectional association between atrial fibrillation and myocardial infarction. Vol. 20, Nature Reviews Cardiology. Nature Research; 2023. hlm. 631–44.
40. Noubiap JJ, Nyaga UF, Ndoadoumgue AL, Nkeck JR, Ngouo A, Bigna JJ. Meta-analysis of the incidence, prevalence, and correlates of atrial fibrillation in rheumatic heart disease. Glob Heart. 18 Mei 2020;15(1).
41. Antoun I, Layton GR, Nizam A, Barker J, Abdelrazik A, Eldesouky M, dkk. Hypertension and Atrial Fibrillation: Bridging the Gap Between Mechanisms, Risk, and Therapy. Medicina (B Aires) [Internet]. 19 Februari 2025;61(2):362. Tersedia pada: https://www.mdpi.com/1648-9144/61/2/362
42. Holt A, Gislason GH, Schou M, Zareini B, Biering-Sørensen T, Phelps M, dkk. New-onset atrial fibrillation: Incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people. Eur Heart J. 21 Agustus 2020;41(32):3072–9.
43. Čarná Z, Osmančík P. The Effect of Obesity, Hypertension, Diabetes Mellitus, Alcohol, and Sleep Apnea on the Risk of Atrial Fibrillation. Physiol Res. 1 Desember 2021;70:511–25.
44. Liu LM, Shen LS, Liu SY, Tu B, Li GL, Hu F, dkk. Correlations between low thyroid function and incidence of atrial fibrillation in hypertrophic obstructive cardiomyopathy. Chronic Dis Transl Med. 1 Maret 2020;6(1):35–45.
45. Ding WY, Gupta D, Wong CF, Lip GYH. Pathophysiology of atrial fibrillation and chronic kidney disease. Vol. 117, Cardiovascular Research. Oxford University Press; 2021. hlm. 1046–59.
46. Corica B, Tartaglia F, Oliva A, Raparelli V, Cangemi R, Basili S, dkk. Prevalence of new-onset atrial fibrillation in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Intern Emerg Med. 1 Januari 2023;18(1):127–35.
47. Romiti GF, Corica B, Pipitone E, Vitolo M, Raparelli V, Basili S, dkk. Prevalence, management and impact of chronic obstructive pulmonary

disease in atrial fibrillation: A systematic review and meta-Analysis of 4,200,000 patients. Eur Heart J. 2021;42(35):3541-3554C.
48. Sinha T, Joshi HM, Patel B, Stanikzai H, Hussaini H, Chaudhari SS, dkk. The Association Between Gastroesophageal Reflux Disease and Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cureus [Internet]. 1 Februari 2025; Tersedia pada: https://www.cureus.com/articles/334416-the-association-between-gastroesophageal-reflux-disease-and-atrial-fibrillation-a-systematic-review-and-meta-analysis
49. Chen Z, Liu J, Zhou F, Li H, Zhang XJ, She ZG, dkk. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia. Vol. 128, Circulation Research. Lippincott Williams and Wilkins; 2021. hlm. 1747–65.
50. Ho TC, Chen YC, Lin CC, Tai HC, Wei CY, Yeh YH, dkk. Reduced Risk of Atrial Fibrillation Following Cholecystectomy: A Nationwide Population-Based Study. Front Aging Neurosci. 2 September 2021;13.
51. Lin D, Chen Y, Yong J, Wu S, Zhou Y, Li W, dkk. Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation? Front Cardiovasc Med. 2021;8.
52. Reig-Garcia G, Camara-Liebana D, Jiménez-Quiñones R, Vilanó-Vives J, Figa-Vaello J, Garre-Olmo J, dkk. Control of Therapeutic Levels of Anticoagulation and Associated Factors: A Prospective Cohort Study. J Prim Care Community Health. 2022;13.
53. Yimer NS, Abiye AA, Hussen SU, Tadesse TA. Anticoagulation Control, Outcomes, and Associated Factors in Patients with Atrial Fibrillation Receiving Warfarin at Tertiary Care Hospital in Ethiopia. Clinical and Applied Thrombosis/Hemostasis. 2021;27.
54. Ekiz M, Duran L, Akdemir HU, Aksoy İ. The Factors Associated With Bleeding In Patients Using Warfarin. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi. 31 Desember 2021;23(3):482–91.
55. Tan CSS, Lee SWH. Warfarin and food, herbal or dietary supplement interactions: A systematic review. Vol. 87, British Journal of Clinical Pharmacology. Blackwell Publishing Ltd; 2021. hlm. 352–74.
56. Soyombo BM, Taylor A, Gillard C, Wilson C, Bailey Wheeler J. Impact of body mass index on 90-day warfarin requirements: a retrospective chart review. Ther Adv Cardiovasc Dis. 2021;15.
57. Westerman S, Wenger N. Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes. Curr Cardiol Rev. 5 Desember 2019;15(2):136–44.
58. Uskur T, Güven O, Demireller M. Warfarin in the Emergency Service: Drug Interactions and Clinical Considerations. Turkish Journal of Clinics and Laboratory. 1 Juli 2024;15(2):234–9.
59. Engell AE, Svendsen ALO, Lind BS, Andersen CL, Andersen JS, Willadsen TG, dkk. Drug-drug interaction between warfarin and statins: A Danish cohort study. Br J Clin Pharmacol. 1 Februari 2021;87(2):694–9.

60. Tng EL, Tiong YS, Aung AT, Chong NYY, Wang Z. Efficacy and safety of anticoagulation in thyrotoxic atrial fibrillation: a systematic review and meta-analysis. Endocr Connect. 1 Mei 2022;11(5).
61. Dunvald ACD, Nielsen F, Olsen DA, Ernst MT, Donnelly L, Soto-Pedre E, dkk. Initiation of glucose-lowering drugs reduces the anticoagulant effect of warfarin—But not through altered drug metabolism in patients with type 2 diabetes. Br J Clin Pharmacol. 1 Agustus 2023;89(8):2529–41.
62. Sood N, Ashton V, Bessada Y, Galli K, Bookhart BK, Coleman CI. Effectiveness and Safety of Rivaroxaban Versus Warfarin among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea. TH Open. Januari 2023;07(01):e82–93.
63. Randhawa MS, Vishwanath R, Rai MP, Wang L, Randhawa AK, Abela G, dkk. Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease A Systematic Review and Meta-analysis. Vol. 3, JAMA Network Open. American Medical Association; 2020. hlm. E202175.
64. Zhang X, Chen GY, Wang ZX, Li XH, Luo R, Li YG, dkk. Nonalcoholic fatty liver disease impacts the control of the international normalized ratio in patients with atrial fibrillation. Ann Transl Med. Agustus 2020;8(16):1008–1008.
65. Landayan RP, Saint-Felix S, Williams A. Probable Interaction Between Warfarin and the Combination of Remdesivir With Dexamethasone for Coronavirus Disease 2019 (COVID-19) Treatment: A 2 Case Report. J Pharm Pract. 1 Desember 2022;35(6):1039–43.
66. Chen X, Li A, Kuang Y, Ma Q. Gastroesophageal reflux disease and atrial fibrillation: a bidirectional Mendelian randomization study. Int J Med Sci. 2024;21(7):1321–8.
67. Fahmi AM, Elewa H, El Jilany I. Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review. Vol. 44, International Journal of Clinical Pharmacy. Springer Science and Business Media Deutschland GmbH; 2022. hlm. 599–607.
68. Asiimwe IG, Zhang EJ, Osanlou R, Jorgensen AL, Pirmohamed M. Warfarin dosing algorithms: A systematic review. Vol. 87, British Journal of Clinical Pharmacology. Blackwell Publishing Ltd; 2021. hlm. 1717–29.
69. Sun B, Yew PY, Wen YF, Chi CL, Straka RJ. Comparison of the Warfarin Dosing and Outcomes in Hmong Versus East Asians Patients: Real-World Data From an Integrated Healthcare System. Cureus. 7 September 2022;